Introduction: Cytomegalovirus (CMV) infection represents a common cause of morbidity and mortality in kidney transplant recipients (KTR). The NF-kB signaling pathway is highly involved in the pathogenesis of CMV infection. The -94ins/delATTG functional polymorphism in the promoter of NFKB1 has been associated with low intracellular levels of the protein and high incidence of inflammatory and autoimmune disease. In this study, we evaluated the association of this NFKB1 polymorphism with the risk of CMV infection.
| INTRODUC TI ON
Cytomegalovirus (CMV) infection represents a common infectious disease among kidney transplant recipients (KTR) that can directly cause fever, leukopenia, thrombocytopenia with or without specific organ dysfunction. It may lead to indirect effects on the host's immune response such as acute or chronic rejection, reducing longterm graft function, increasing risk of other opportunistic infections, malignancies, and reducing patient survival. 1 The incidence of CMV infection and serious clinical complications are highly dependent on the serostatus of recipient (R) and donor (D) with D+R− transplant showing the highest risk.
2 Studies on anti-CMV strategies usually distinguish between these risk categories, thereby often summarizing the D+R+ and D−R+ groups in an intermediate-risk category.
Currently, universal prophylaxis and preemptive strategies are the two viable approaches for the prevention of CMV syndrome and disease. Apart from high risk category, considering the currently available evidence, preemptive therapy and antiviral prophylaxis are equally successful in preventing major complications of CMV infection in kidney allograft recipients, including CMV disease, allograft loss, and patient death. [3] [4] [5] [6] Universal prophylaxis presents some substantial problems linked to drug toxicity, late CMV disease, and development of ganciclovir-resistant mutants. 6 Therefore, we need to identify new risk factors, independent from CMV serostatus, that can predict CMV infection onset, particularly in intermediate-risk patients, helping the management of this infective complication, and in particular the decision between prophylaxis and preemptive therapy.
The role of NF-kB in CMV infection is highly counterintuitive.
In effect, NF-kB signaling leads to the transcription of a wealth of inflammatory mediators contributing to the development of host response to infection. 7 NF-kB signaling pathway is also highly involved in the pathogenesis of CMV infection, indeed its activation can also facilitate CMV viral replication, through the activation of the promoter regulating immediate-early (IE) gene expression, since several NF-kB-binding sites are located on IE gene promoter.
8,9
NF-kB is a heterodimeric complex composed of NFKB1 (p50) and
RelA (p65). Under normal physiological condition, NF-kB is maintained in the cytosol in inactive state complexed with the inhibitory protein inhibitor kappa B-alpha (IkBα). When the IkB kinase (IKK) complex phosphorylates IkBα, it is ubiquitinated and degraded by the proteasomes, allowing translocation of NFKB1 and RelA into the nucleus where it binds to specific DNA sequences in the promoters of target genes. 10 Recently, a functional polymorphism in the promoter of NFKB1
(-94ins/delATTG) has been associated with an increased risk of developing inflammatory, infectious and autoimmune diseases as well as susceptibility of several cancers. However, to date, there are no data about the association between functional promoter polymorphism of NFKB1 and CMV infection after kidney transplantation.
The NFKB1 -94ins/delATTG polymorphism is an insertion/deletion of four bases in the promoter region of the NFKB1 gene encoding both the NFKB1 isoforms, p50 and p105. The allele containing the deletion is less able to bind transcription factors and producing lower transcript levels in luciferase reporter systems. Consequently, carriers of the deletion allele have lower intracellular levels of NFKB1. 11, 12 In this study, we tested the hypothesis that -94ins/delATTG NFKB1 promoter polymorphism would influence the risk of CMV infection. CMV recurrence was defined as detection of viremia >650 copies/mL of whole blood in the first year after the first CMV infection.
| MATERIAL S AND ME THODS

| Patients and clinical definitions
Acute graft rejection was scored and graded by means of the Banff schema. Biopsy-proven acute graft rejection (BPAR) was treated with intravenous high-pulse dose of steroids or anti-thymocyte globulin as clinically and histologically indicated.
Delayed Graft Function (DGF) was defined as the necessity for dialysis in the first week after surgery. 
| Evaluation
| Genotyping the -94ins/delATTG promoter polymorphism
Genomic DNA was extracted from peripheral blood leukocytes by using the Wizard Genomic DNA Purification kit (Promega, Madison, WI, USA), following the manufacturer's instructions. At a later stage, DNA was quantified by spectrophotometric reading absorbance at 260 nm with Eppendorf Bio Spectrometers.
The -94ins/delATTG polymorphism was assayed by polymerase chain reaction (PCR) amplification using the primers described by Karban et al. 11 Products were digested by the enzyme PflMl, which cleaves the -94ins ATTG containing product twice and the -94de-lATTG containing product once, and analyzed on a 2.5% agarose gel. Survival free from CMV infection was estimated using the KaplanMeier method and compared for statistical significance using the logrank method. Proportional hazard Cox regression model was used to evaluate the independent association between -94ins/delATTG NFKB1 polymorphism and CMV infections. CMV infection recurrence was analyzed using the Prentice, Williams, and Peterson (PWP) model. 14 A P value <0.05 was considered statistically significant. All the statistical analyses were performed using R and relative packages (version 3.3.1. The R Foundation for Statistical Computing, Vienna, Austria).
| Statistical analysis
| RE SULTS
We analyzed the -94ins/delATTG NFKB1 promoter polymorphism in 189 
| Patients characteristics
Main demographic and baseline characteristics of participants are shown in Table 1 . The mean age of the recipients at the time of 0.088-0.57; P = 0.0002). DGF was instead associated to a high risk of CMV infection (1.088, 1.052-1.126; P < 0.0001; Table 2 ).
| NFKB1 -94ins/delATTG polymorphism and CMV infection
To investigate the role of -94ins/delATTG NFKB1 promoter polymorphism on CMV viremia recurrence in the first year after the first CMV infection, we performed univariate and multivariate PWP model. At multivariate analysis, independently from other evaluated variables, the del carriers KTRs showed a lower risk for CMV recurrence respect to homozygous ins/ins KTRs (HR 0.307, 95% CI:
0.060-0.753, P = 0.012; Table 3 ).
| D ISCUSS I ON
In our study, we investigated the association of a NFKB1 functional promoter polymorphism with the risk of CMV infection onset after kidney transplantation. Our results showed, for the first time, that the patients with the NFKB1 -94ins/ins genotype had higher risk of cancer, asthma, lung fibrosis, diabetes, AIDS, atherosclerosis, stroke, and chronic intestinal inflammation. 15, 16 In addition, these polymorphisms have been correlated to the outcome of several diseases, as multiple myeloma and acute renal rejection. 17, 18 In particular, a recent study described the functional polymorphism of NFKB1, -94ins/ del ATTG, demonstrating its association with ulcerative colitis.
11
Moreover, Varga et al showed that in myeloma patients treated with
Bortezomib, a potent inhibitor of the canonical activation of the NF-kB pathway, the genotype -94 ins/ins was associated with a better outcome and response to treatment with respect to -94 del/del carriers. 17 It is well known that NF-kB signaling pathway is highly involved in the pathogenesis of CMV infection. Indeed, although the induction of NF-kB transcription is necessary for the resolution of infection as mechanism of host defense, virus has evolved to include NF-kB-binding sites on the promoter of its key replication elements, promoting viral replication. 19 One interpretation of this phenomenon is that the virus exploits the NF-kB pathway to drive its own transcriptional events, because it is strongly activated during infection. Therefore, it would seem clear that NF-kB activation plays a positive role for CMV replication and that inhibiting NF-kB activation would be a useful strategy to block virus replication. 15, [20] [21] [22] In particular, NF-kB activation induced by CMV plays a pivotal role in the transactivation of the major immediate-early promoter and in the production of IE proteins, necessary for CMV replication. 9, 23, 24 Kowalik et al demonstrated an increased nuclear NF-kB activity in CMV-infected fibroblasts. 25 In a more detailed examination of the The major limitation of the study was the analysis of ins/del and del/del patients as a single group (deletion carriers) forced by the low frequency of del/del patients in our cohort. This has limited the possibility to evaluate whether homozygote patients could have a different outcome from heterozygote. This analysis seems to be appropriate and relevant when the polymorphism is rare; in this case, the data may be analyzed assuming a prespecified genetic model. 27 Moreover, most patients enrolled were D + R + limiting the statistical power regression regarding differences in outcome by Donor/ Recipient CMV serostatus.
In conclusion, our findings suggest that pretransplantation screening for NFKB1 -94ins/delATTG functional polymorphism may predict CMV infection. This could improve the management of CMV infection providing useful information which may direct the decision to start antiviral treatment in terms of prophylaxis and/or preemptive strategy.
ACK N OWLED G M ENT
The authors gratefully acknowledge Armentano F, Ferraro G, and Greco A for their nursing assistance in this study.
AUTH O R CO NTR I B UTI O N S
LF, GP, and LRA performed study; DL analyzed data; PP and TR collected data; VD, LS, TG, BM, and AB contributed with results interpretation and paper review; PA and RB designed the study and approved the submitted and final versions.
O RCI D
Renzo Bonofiglio https://orcid.org/0000-0003-3871-2460
